Lantheus Holdings, Inc. (LNTH) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $82.74. It has a SharesGrow Score of 83/100, indicating a strong investment profile with 7 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of LNTH = $158.94 (+92.1% from the current price, the stock appears undervalued). Analyst consensus target is LNTH = $87 (+5.1% upside).
Valuation: LNTH trades at a trailing Price-to-Earnings (P/E) of 22.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.06.
Financials: revenue is $1.5B, +19.2%/yr average growth. Net income is $234M, growing at +344.8%/yr. Net profit margin is 15.2% (healthy). Gross margin is 61.1% (-1.1 pp trend).
Balance sheet: total debt is $738,000 against $1.1B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.7 (strong liquidity). Debt-to-assets is 0%. Total assets: $2.2B.
Analyst outlook: 13 / 17 analysts rate LNTH as buy (76%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 78/100 (Pass), Growth 90/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 70/100 (Pass), Future 73/100 (Pass), Income 70/100 (Pass).
